Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
20.57B
Market cap20.57B
Price-Earnings ratio
-6.90
Price-Earnings ratio-6.90
Dividend yield
Dividend yield
Average volume
5.36M
Average volume5.36M
High today
$52.39
High today$52.39
Low today
$50.55
Low today$50.55
Open price
$51.96
Open price$51.96
Volume
4.85M
Volume4.85M
52 Week high
$59.55
52 Week high$59.55
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 20.57B, Moderna(MRNA) trades at $52.10. The stock has a price-to-earnings ratio of -6.90.

On 2026-04-08, Moderna(MRNA) stock traded between a low of $50.55 and a high of $52.39. Shares are currently priced at $52.10, which is +3.1% above the low and -0.6% below the high.

Moderna(MRNA) shares are trading with a volume of 4.85M, against a daily average of 5.36M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

MRNA News

TipRanks 1d
Moderna price target raised to $35 from $30 at RBC Capital

RBC Capital raised the firm’s price target on Moderna (MRNA) to $35 from $30 and keeps a Sector Perform rating on the shares as part of the firm’s broader resea...

TipRanks 1d
Roivant Sciences price target raised to $34 from $30 at Jefferies

Jefferies analyst Dennis Ding raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $30 and keeps a Buy rating on the shares. A key question pos...

Nasdaq 1d
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500.

Key Points This company soared into the spotlight with its first product a few years ago. But in recent years, the company's earnings and stock price declined...

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500.

Analyst ratings

69%

of 26 ratings
Buy
15.4%
Hold
69.2%
Sell
15.4%

More MRNA News

TipRanks 5d
Moderna Advances Phase 3 H5 Bird Flu Shot, Expanding Its Pandemic Vaccine Pipeline

Moderna (MRNA) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions D...

Simply Wall St 6d
Why Moderna Is Down 6.6% After Its ‘Moderna 2.0’ Cancer-Vaccine Pivot - And What's Next

In late March 2026, Moderna participated in the World Vaccine Congress Washington and the 4th annual Entrepreneurship Summit, where senior leaders highlighted i...

Why Moderna Is Down 6.6% After Its ‘Moderna 2.0’ Cancer-Vaccine Pivot - And What's Next

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.